Clinical Trials Logo

Clinical Trial Summary

The purpose of this 2016/17 pilot study is to improve the combination of a card-based adverse drug reaction (ADR) system and the use of routine data to collect adverse events following vaccination with seasonal influenza vaccines, as per European Medicines Agency (EMA) guidance and Pharmacovigilance Risk Assessment Committee of EMA (PRAC) requirements, and to identify additional data which may need to be collected in order to appropriately address the requirement.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02893878
Study type Observational
Source GlaxoSmithKline
Contact
Status Completed
Phase N/A
Start date September 2016
Completion date November 2016

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03275389 - A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years Phase 1
Recruiting NCT02867358 - A Clinical Trial of KT07 Capsule in the U.S.A Phase 2
Enrolling by invitation NCT02883972 - Childhood Influenza Immunisation Invitation Trial in Schools N/A
Completed NCT02984280 - Specific Respiratory Infections as Triggers of Acute Medical Events N/A
Completed NCT02998996 - Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU Phase 1/Phase 2
Completed NCT02914275 - A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age. Phase 3
Completed NCT02545543 - A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age Phase 3
Completed NCT02621164 - Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents Phase 3
Completed NCT02212106 - A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years Phase 4
Completed NCT02243774 - Mail Outreach To Increase Vaccination Acceptance Through Engagement N/A
Completed NCT02344134 - Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects Phase 3
Completed NCT01674205 - Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines Phase 1
Completed NCT01390025 - Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza Phase 1
Completed NCT01381029 - Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals N/A
Active, not recruiting NCT03445468 - Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents Phase 3
Active, not recruiting NCT03283319 - Panblok H7 Vaccine Adjuvanted With AS03 or MF59 Phase 2
Completed NCT03278067 - Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines: Pilot Study in England N/A
Recruiting NCT02885246 - Prevalence, Strain Circulation and Disease Burden Study of Seasonal Influenza A and B in Panama, Selected Countries of Central America and the Caribbean From the Year 2010 to 2015 N/A
Recruiting NCT03438487 - Flucelvax (TIVc or QIVc) Pregnancy Registry N/A
Completed NCT00995982 - VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years Phase 1